Holen Sie sich die Stockscreener-App
17.03
1.55%
0.26
Vorhandelsmarkt:
17.00
-0.03
-0.18%
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short Interest - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Lowered by GSA Capital Partners LLP - MarketBeat
Acadia Pharmaceuticals Grants Stock Options, RSUs to 23 New Employees in Growth Push | ACAD Stock News - StockTitan
ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com
Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - Yahoo Finance
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth - MSN
US Bancorp DE Has $507,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals: Proving The Naysayers Wrong (NASDAQ:ACAD) - Seeking Alpha
What is Leerink Partnrs' Forecast for ACAD FY2026 Earnings? - MarketBeat
FY2024 Earnings Estimate for ACAD Issued By HC Wainwright - MarketBeat
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates - MSN
ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Acadia Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for ACAD - Nasdaq
Acadia Pharmaceuticals price target lowered to $32 from $33 at Canaccord - TipRanks
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2024 Earnings Call Transcript - Insider Monkey
Equities Analysts Issue Forecasts for ACAD FY2027 Earnings - MarketBeat
HC Wainwright Issues Pessimistic Estimate for ACAD Earnings - MarketBeat
ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Simply Wall St
ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Quarterly 10-Q Report - Quartzy
ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results - MarketBeat
Acadia Pharmaceuticals participates in a conference call with JPMorgan - TipRanks
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given Buy Rating at HC Wainwright - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Buy Rating from Needham & Company LLC - MarketBeat
Acadia Pharma Q3 2024 Earnings Preview - MSN
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highligh - GuruFocus.com
ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Acadia: Q3 Earnings Snapshot - Houston Chronicle
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview - BioSpace
Acadia Pharmaceuticals Sees Revenue Growth and Strategic Advances - TipRanks
Acadia Pharmaceuticals reports Q3 EPS , consensus 14c - TipRanks
ACADIA Pharmaceuticals Q3 2024 Earnings: EPS of $0.20 Beats Esti - GuruFocus.com
Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M - MedCity News
Acadia Pharma (ACAD) Tops Q3 EPS by 6c ; Offers Guidance - StreetInsider.com
Acadia Pharma sells priority review voucher for $150 million | Pharmaceutical | The Pharmaletter - The Pharma Letter
Acadia sells speedy drug review voucher for $150M - BioPharma Dive
Acadia makes $100M profit from $150M pediatric voucher sale - Fierce Biotech
Acadia lands $150M sale of rare pediatric PRV - Endpoints News
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - BioSpace
Acadia Pharmaceuticals to Sell Rare Pediatric Disease Priority Review Voucher - MarketWatch
Acadia Pharma sells Rare Pediatric Disease Priority Review Voucher for $150M - TipRanks
Acadia Pharma (ACAD) to Sell Rare Pediatric Disease Priority Review Voucher for $150M - StreetInsider.com
AlphaCentric Advisors LLC Has $615,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024 - Insider Monkey
10 Worst-Performing Growth Stocks in 2024 - Insider Monkey
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
ACADIA Pharmaceuticals (ACAD) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Emerging Insights: Market Trends in Multiple System Atrophy (MSA) Market | Acadia Pharmaceuticals Inc - EIN News
ACADIA Pharmaceuticals' SWOT analysis: stock outlook mixed as DAYBUE uptake lags By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals' SWOT analysis: stock outlook mixed as DAYBUE uptake lags - Investing.com India
ACADIA Pharmaceuticals stock hits 52-week low at $14.31 By Investing.com - Investing.com Australia
ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 1-Year LowWhat's Next? - MarketBeat
ACADIA Pharmaceuticals stock hits 52-week low at $14.31 - Investing.com India
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):